Inactive Instrument

Analyst Reco. Meridian Bioscience, Inc.

Equities

HC Wainwright Downgrades Meridian Bioscience to Neutral From Buy, Adjusts Price Target to $34 From $30	22-07-08	MT
William Blair Downgrades Meridian Bioscience to Market Perform from Outperform	22-07-07	MT
HC Wainwright Adjusts Meridian Bioscience's Price Target to $30 From $28, Keeps Buy Rating	22-02-07	MT
MERIDIAN BIOSCIENCE : HC Wainwright Adjusts Meridian Bioscience's Price Target to $27 From $30, Keeps Buy Rating	21-08-09	MT
MERIDIAN BIOSCIENCE : HC Wainwright Adjusts Meridian Bioscience PT to $30 From $32, Maintains Buy Rating	21-05-10	MT
MERIDIAN BIOSCIENCE : HC Wainwright Adjusts Meridian Bioscience's Price Target to $32 From $34, Keeps Buy Rating	21-02-24	MT
MERIDIAN BIOSCIENCE : Piper Sandler Adjusts Price Target on Meridian Bioscience to $34 From $26, Reiterates Overweight Rating	21-02-08	MT
MERIDIAN BIOSCIENCE : HC Wainwright Adjusts Price Target on Meridian Bioscience to $34 From $30, Maintains Buy Rating	21-02-08	MT
MERIDIAN BIOSCIENCE : Piper Sandler Adjusts Meridian Bioscience's Price Target to $26 From $24, Maintains Overweight Rating	20-11-16	MT
MERIDIAN BIOSCIENCE : HC Wainwright Adjusts Meridian Bioscience's Price Target to $30 From $34, Keeps at Buy	20-11-16	MT
Meridian Bioscience Reports Second Quarter 2020 Operating Results; Raises Guidance on Strength of COVID-19 Related Products	20-05-08	GL

No results for this search